peter attia on semaglutide 184 - [AMA #29 Sneak Peek] GLP-1 Agonists: The Future of Treating Obesity? Semaglutide Insights | Ask Huberman

Maternal body mass index, gestational weight gain, and the risk of overweight and obesity across childhood: an individual participant data meta-analysis

In June 2021, the FDA approved Semaglutide (Wegovy), a GLP-1 receptor agonist developed by Novo Nordisk, for use as a weight loss drug

We believe that if even a single patient feels the need to turn to potentially unsafe and unapproved knockoff alternatives, that's one too many," said Dave Moore, Executive Vice President, US Operations of Novo Nordisk Inc

The delivery concept is plausible, and small human studies support biological delivery from tested formulations